Pharmafile Logo
Pharmafocus logo
Advanced Search

RA

Showing 15 posts of 32 posts found.

New data for Pfizer arthritis pill

September 18, 2012
Research and Development, Sales and Marketing JAK, Pfizer, RA, tofacitinib

Pfizer is to release more data for its investigational rheumatoid arthritis (RA) pill tofacitinib which it hopes will demonstrate its …

News

Pfizer’s RA pill impresses in Phase III

August 1, 2012
Research and Development, Sales and Marketing FDA, JAK, Pfizer, RA

Pfizer’s investigational arthritis drug tofacitinib has beaten methotrexate in a head-to-head study. Tofacitinib, an oral Janus kinase (JAK) inhibitor, is …

News
Humira image

Humira powers ahead as Abbott prepares split

July 19, 2012
Sales and Marketing AbbVie, Abbott, Humira, RA

Humira maintained its rapid growth in the second quarter, helping keep Abbott buoyant ahead of its split into two separate …

News
EMA HQ

EMA clarifies antibodies development

June 20, 2012
Manufacturing and Production, Research and Development, Sales and Marketing CMPHU, EMA, RA, antibodies

European regulators have issued final guidance on how pharma manufacturers should develop drugs containing monoclonal antibodies. Typically used in treatments …

News
RoActemra image

RoActemra superior to Humira as single-agent therapy

June 7, 2012
Research and Development, Sales and Marketing Humira, Orencia, RA, RoActemra, Roche. ADACTA

Roche’s RoActemra (tocilizumab) is more effective in treating rheumatoid arthritis as a single agent than market leader Humira, a new …

News

Pfizer’s RA drug on course for approval

May 10, 2012
Sales and Marketing Humira, JAK inhibitor, Pfizer, RA, rheumatoid arthritis, tofacitinib

An FDA advisory committee has recommended for approval Pfizer’s new rheumatoid arthritis treatment tofacitinib.The Arthritis Advisory Committee voted 8-2 to …

News
RoActemra image

Roche’s RoActemra beats Humira in arthritis study

March 5, 2012
Research and Development, Sales and Marketing Humira, RA, RoActemra, Roche, arthritis

Roche’s rheumatoid arthritis drug RoActemra has beaten Abbott’s Humira in a head-to-head study. The Phase IV trial showed that RoActemra …

News
Abbott image

Abbott buys into Galapagos’ RA candidate

February 29, 2012
Research and Development, Sales and Marketing Abbott, Galapagos, Humira, JAK, RA, TNF

Abbott has struck a deal with Galapagos to develop and commercialise a promising oral JAK1 inhibitor to treat multiple autoimmune …

News

Roche discontinues arthritis drug trials

May 20, 2010
Sales and Marketing RA, Roche

Roche and Biogen Idec will discontinue clinical trials for rheumatoid arthritis drug ocrelizumab. Development of the RA treatment was halted …

News

Pfizer’s new RA treatment shows promise

November 11, 2009
Research and Development, Sales and Marketing Pfizer, RA

 Pfizer has announced data from two clinical studies of its developmental rheumatoid arthritis candidate.CP-690550 is the first in a new …

News

Simponi approved in Europe

October 8, 2009
Sales and Marketing RA, Simponi, TNF

 Rheumatic disease drug Simponi has received marketing approval for Europe, where it will be marketed by Schering-Plough.The drug is indicated …

News

Patients on Enbrel work longer, says study

September 7, 2009
Research and Development, Sales and Marketing Enbrel, RA

 Rheumatoid arthritis patients taking Enbrel are able to keep working for longer, according to a new study comparing its affects …

News

TNF blockers must carry children’s cancer warning

August 7, 2009
Research and Development, Sales and Marketing FDA, RA, TNF

The FDA has ruled that TNF blocker drugs should carry new warnings of the increased risk of certain cancers for …

News

Centocor launches online arthritis talk show

August 4, 2009
Medical Communications, Sales and Marketing Centacor, RA, US, digi

An online talk show for rheumatoid arthritis patients has been launched in the US with the aim of raising awareness …

News

Rheumatoid arthritis delays criticised

July 16, 2009
Sales and Marketing NHS, RA

An official report into the treatment of people with rheumatoid arthritis (RA) has criticised a lack of co-ordination between different …

News
The Gateway to Local Adoption Series

Latest content

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026

Alvotech appoints Lisa Graver as CEO

February 3, 2026

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026